Rockwell Medical,Inc. (NASDAQ:RMTI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02. Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain
Officers

On March1, 2017, Mr.Ken Holt advised the Board of Directors of
Rockwell Medical,Inc. (the Company) that he has chosen not
to stand for reelection as a director of the Company at the
Companys 2017 Annual Meeting of Shareholders (the 2017 Annual
Meeting).

Item 8.01 Other Events

Attached hereto as Exhibit99.1, and incorporated herein by
reference, is a copy of a press release issued by the Company on
March2, 2017 announcing, among other things, that Mr.Holt has
chosen not to stand for reelection as a director at the 2017
Annual Meeting and that Mr.David Domzalski has been nominated to
join the Companys board of directors, replacing Mr.Holt.

Item 9.01 Financial Statements and
Exhibits

Important Additional Information and Where to Find
It

Rockwell Medical,Inc., its directors and certain of its executive
officers may be deemed to be participants in the solicitation of
proxies from the Companys shareholders in connection with the
matters to be considered at the 2017 Annual Meeting of
Shareholders. Information regarding the names of the Companys
directors and executive officers and their respective interests
in the Company by security holdings or otherwise can be found in
the Companys proxy statement for its 2016 Annual Meeting of
Shareholders, filed with the Securities and Exchange Commission
(SEC) on April18, 2016. To the extent holdings of the
Companys securities have changed since the amounts set forth in
the Companys proxy statement for the 2016 Annual Meeting of
Shareholders, such changes have been reflected on Initial
Statements of Beneficial Ownership on Form3 or Statements of
Change in Ownership on Form4 filed with the SEC. These documents
are available free of charge at the SECs website at www.sec.gov.
Rockwell Medical,Inc. intends to file a proxy statement and
accompanying WHITE proxy card
with the SEC in connection with the solicitation of proxies from
shareholders in connection with the matters to be considered at
the 2017 Annual Meeting of Shareholders. Additional information
regarding the identity of participants, and their direct or
indirect interests, by security holdings or otherwise, will be
set forth in the Companys proxy statement for its 2017 Annual
Meeting, including the schedules and appendices thereto.
Investors and shareholders are strongly encouraged to
read any such proxy statement and the accompanying WHITE
proxy card and other documents filed by Rockwell Medical,Inc.
with the SEC carefully and in their entirety when they become
available, as they will contain important information.
Shareholders will be able to obtain the proxy statement, any
amendments or supplements to the proxy statement, the
accompanying WHITE proxy card,
and other documents filed by Rockwell Medical,Inc. with the SEC
for no charge at the SECs website at www.sec.gov. Copies will
also be available at no charge by writing to Rockwell
Medical,Inc., Attn: Secretary, 30142 S. Wixom Road, Wixom,
Michigan, 48393.

About Rockwell Medical, Inc. (NASDAQ:RMTI)

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.

Rockwell Medical, Inc. (NASDAQ:RMTI) Recent Trading Information

Rockwell Medical, Inc. (NASDAQ:RMTI) closed its last trading session down -0.03 at 6.00 with 174,481 shares trading hands.